A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer

Cancer Research

Volumn 63, Issue 12, 2003, Pages 3181-3188

  Wirth, Thomas ^a   Zender, Lars ^a   Schulte, Bernd ^a   Mundt, Bettina ^a   Plentz, Ruben ^a   Lenhard Rudolph, Karl ^a   Manns, Michael ^a   Kubicka, Stefan ^a   Kühnel, Florian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; ONYX 015; PROTEIN P53; TELOMERASE; VIRUS PROTEIN; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; ENZYME REACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOCUS; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; BIOLOGICAL THERAPY; CARCINOMA, HEPATOCELLULAR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HELA CELLS; HEPATOCYTES; HUMANS; IMMUNOTHERAPY, ACTIVE; LIVER NEOPLASMS; LUMINESCENT PROTEINS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; TATA BOX; TELOMERASE; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; VIRAL VACCINES; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038745637     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Blasco, M. A., Lee, H. W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., and Greider, C. W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell, 91: 25-34, 1997.
2. Lee, H. W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., Greider, C. W., and DePinho, R. A. Essential role of mouse telomerase in highly proliferative organs. Nature (Lond.), 392: 569-574, 1998.
3. Rudolph, K. L., Chang, S., Lee, H. W., Blasco, M., Gottlieb, G. J., Greider, C., and DePinho, R. A. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell, 96: 701-712, 1999.
4. Greider, C. W. Telomere length regulation. Annu. Rev. Biochem., 65: 337-365, 1996.
5. Weinrich, S. L., Pruzan, R., Ma, L., Ouellette, M., Tesmer, V. M., Holt, S. E., Bodnar, A. G., Lichtsteiner, S., Kim, N. W., Trager, J. B., Taylor, R. D., Carlos, R., Andrews, W. H., Wright, W. E., Shay, J. W., Harley, C. B., and Morin, G. B. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Genet., 17: 498-502, 1997.
6. Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. Extension of life-span by introduction of telomerase into normal human cells. Science (Wash. DC), 279: 349-352, 1998.
7. Vaziri, H., and Benchimol, S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol., 8: 279-282, 1998.
8. Shay, J. W., and Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer, 33: 787-791, 1997.
9. Poole, J. C., Andrews, L. G., and Tollefsbol, T. O. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene, 269: 1-12, 2001.
10. Greenberg, R. A., O'Hagan, R. C., Deng, H., Xiao, Q., Hann, S. R., Adams, R. R., Lichtsteiner, S., Chin, L., Morin, G. B., and DePinho, R. A. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene, 18: 1219-1226, 1999.
11. Wu, K. J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J., and Dalla-Favera, R. Direct activation of TERT transcription by c-MYC. Nat. Genet., 21: 220-224, 1999.
12. Kanaya, T., Kyo, S., Hamada, K., Takakura, M., Kitagawa, Y., Harada, H., and Inoue, M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res., 6: 1239-1247, 2000.
13. Abdul-Ghani, R., Ohana, P., Matouk, I., Ayesh, S., Ayesh, B., Laster, M., Bibi, O., Giladi, H., Molnar-Kimber, K. Sughayer, M. A., de Groot, N., and Hochberg, A. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol. Ther., 2: 539-544, 2000.
14. Koga, S., Hirohata, S., Kondo, Y., Komata, T., Takakura, M., Inoue, M., Kyo, S., and Kondo, S. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter PG -. Hum. Gene Ther., 11: 1397-1406, 2000.
15. Koga, S., Hirohata, S., Kondo, Y., Komata, T. Takakura, M., Inoue, M., Kyo, S., and Kondo, S. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo. Anticancer Res., 21: 1937-1943, 2001.
16. Komata, T., Koga, S., Hirohata, S., Takakura, M., Germano, I. M., Inoue, M., Kyo, S., Kondo, S., and Kondo, Y. A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int. J. Oncol., 19: 1015-1020, 2001.
17. Komata, T., Kondo, Y., Kanzawa, T. Hirohata, S., Koga, S., Sumiyoshi, H., Srinivasula, S. M., Barna, B. P., Germano, I. M. Takakura, M., Inoue, M., Alnemri, E. S., Shay, J. W., Kyo, S., and Kondo, S. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res., 61: 5796-5802, 2001.
18. Plumb, J. A., Bilsland, A., Kakani, R., Zhao, J., Glasspool, R. M., Knox, R. J., Evans, T. R., and Keith, W. N. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene, 20: 7797-7803, 2001.
19. Komata, T., Kondo, Y., Kanzawa, T., Ito, H., Hirohata, S., Koga, S., Sumiyoshi, H., Takakura, M., Inoue, M., Barna, B. P., Germano, I. M., Kyo, S., and Kondo, S. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum. Gene Ther., 13: 1015-1025, 2002.
20. Gu, J., Kagawa, S., Takakura, M., Kyo, S., Inoue, M., Roth, J. A., and Fang, B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res., 60: 5359-5364, 2000.
21. Majumdar, A. S., Hughes, D. E., Lichtsteiner, S. P., Wang, Z., Lebkowski, J. S., and Vasserot, A. P. The telomerase revere transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther., 8: 568-578, 2001.
22. Gu, J., Andreeff, M., Roth, J. A., and Fang, B. hTERT promoter induces minor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. Gene Ther., 9: 30-37, 2002.
23. Kim, D., Martuza, R. L., and Zwiebel, J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med., 7: 781-787, 2001.
24. Horikawa, I., Cable, P. L., Afshari, C., and Barrett, J. C. Cloning and characterization of the promoter region of human telomerase reverse trancriptase gene. Cancer Res., 59: 826-830, 1999.
25. Mizuguchi, H., and Kay, M. A. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther., 9: 2577-2583. 1998.
26. Kuhnel, F., Zender, L., Paul, Y., Tietze, M. K., Trautwein, C., Manns, M., and Kubicka, S. NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem., 275: 6421-6427, 2000.
27. Morral, N., O'Neal, W. K., Rice, K., Leland, M. M., Piedra, P. A., Aguilar-Cordova, E., Carey, K. D., Beaudet, A. L., and Langston, C. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum. Gene Ther., 13: 143-154, 2002.
28. Curiel, D. T. The development of conditionally replicative adenoviruses for cancer therapy. Clin. Cancer Res., 6: 3395-3399, 2000.
29. Ring, C. J. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol., 83: 491-502, 2002.
30. Bischoff, J. R., Kim, D. H., Williams, A., Heise. C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
31. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A. Hawkins, L., and Kirn, D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med., 6: 1134-1139, 2000.
32. Steinwaerder, D. S., Carlson, C. A., Otto, D. L., Li, Z. Y., Ni, S., and Lieber, A. Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat. Med., 7: 240-243, 2001.
33. Ramachandra, M., Rahman, A., Zou, A., Vaillancourt, M., Howe, J. A., Antelman, D., Sugarman, B., Demers, G. W., Engler, H., Johnson, D., and Shabram, P. Reengineering adenovirus regulatory, pathways to enhance oncolytic specificity and efficacy. Nat. Biotechnol., 19: 1035-1041, 2001.
34. Kurihara, T., Brough, D. E., Kovesdi, I., and Kufe, D. W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUCl antigen. J. Clin. Investig., 106: 763-771, 2000.
35. Li, Y., Yu, D. C., Chen, Y., Amin, P., Zhang, H., Nguyen, N., and Henderson, D. R. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res., 61: 6428-6436, 2001.
36. Matsubara, S., Wada, Y., Gardner, T. A., Egawa, M. Park, M. S., Hsieh, C. L., Zhau, H. E., Kao, C., Kamidono, S., Gillenwater, J. Y., and Chung, L. W. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res., 61: 6012-6019, 2001.
37. Heise, C. C., Williams, A. M., Xue, S., Propst, M., and Kirn, D. H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res., 59: 2623-2628, 1999.
38. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kim, D. H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885, 2000.
39. Kim, D., Hermiston, T., and McCormick, F. ONYX-015: clinical data are encouraging. Nat. Med., 4: 1341-1342, 1998.
40. Hall, A. R., Dix, B. R., O'Carroll, S. J., and Braithwaite, A. W. p53-dependant cell death/apoptosis is required for a productive adenovirus infection. Nat. Med., 4: 1068-1072, 1998.
41. Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., and zur, H. H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol., 72: 9470-9478, 1998.
42. Vollmer, C. M., Ribas, A., Butterfield, L. H., Dissette, V. B., Andrews, K. J., Eilber, F. C., Montejo, L. D., Chen, A. Y., Hu, B., Glaspy, J. A., McBride, W. H., and Economou, J. S. p53 selective and nonselective replication of an E1B deleted adenovirus in hepatocellular carcinoma. Cancer Res., 59: 4369-4374, 1999.
43. Dix, B. R., O'Carroll, S. J., Myers, C. J., Edwards, S. J., and Braithwaite, A. W. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53, Cancer Res., 60: 2666-2672, 2000.
44. Ries, S. J., Brandts, C. H., Chung, A. S., Biederer, C. H., Hann, B. C. Lipner, E. M., McCormick, F., and Michael, K. W. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med., 6: 1128-1133, 2000.